预约演示
更新于：2025-06-07
Adapalene/Benzoyl Peroxide
阿达帕林/过氧苯甲酰
更新于：2025-06-07
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2008-12-08), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C42H38O7 |
InChIKeyUXWMHYHGBDEQJF-UHFFFAOYSA-N |
CAS号1194805-81-6 |
关联
50
项与 阿达帕林/过氧苯甲酰 相关的临床试验TCTR20230810001
A randomized, investigator blind, split-face study of the efficacy of using Eucerin Dermopure to reduce mucocutaneous side effects of adapalene/benzoyl peroxide combination (Epiduo) for the treatment of acne vulgaris.
CTRI/2020/11/028801
A multi-center, double-blind, randomized, placebo controlled, parallel-group study, comparing Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% (Cadila Pharmaceuticals Limited) to Epiduo�® Forte (Adapalene and Benzoyl Peroxide) Gel, 0.3%/2.5%, Galderma Laboratories, L.P.) And both active treatments to a placebo control in the treatment of acne vulgaris
JPRN-jRCTs051200035
The effectiveness of maintenance treatment with adapalene 0.1%-benzoyl peroxide 2.5% gel and benzoyl peroxide 2.5% gel in acne vulgaris patients and the efficacy on acne scar formation
100 项与 阿达帕林/过氧苯甲酰 相关的临床结果
登录后查看更多信息
100 项与 阿达帕林/过氧苯甲酰 相关的转化医学
登录后查看更多信息
100 项与 阿达帕林/过氧苯甲酰 相关的专利（医药）
登录后查看更多信息
34
项与 阿达帕林/过氧苯甲酰 相关的文献（医药）2025-04-01JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
Efficacy of topical treatments for mild‐to‐moderate acne: A systematic review and meta‐analysis of randomized control trials
Review
作者: Young, Trevor ; Yassin, Sallie ; Nicholson, Joey ; Kakpovbia, Efe E. ; Nagler, Arielle R. ; Qian, Yingzhi ; Hu, Jiyuan ; Troxel, Andrea B. ; Milam, Emily C.
Abstract:
Acne is a common skin condition, but little data exist on the comparative efficacy of topical acne therapies. We conducted a systematic review and network meta‐analysis to evaluate the efficacy of topical therapies for mild‐to‐moderate acne. Searches in PubMed/MEDLINE, Cochrane CENTRAL via Ovid, Embase via Ovid and Web of Science were conducted on 29 November 2021. Randomized controlled trials examining ≥12 weeks of topical treatments for acne vulgaris in subjects aged 12 and older were included. Main outcomes were absolute or percent change in acne lesion count and treatment success on the Investigator's Global Assessment scale. Thirty‐five randomized clinical trials with 33,472 participants comparing nine different topical agents were included. Adapalene‐benzoyl peroxide (BPO), clindamycin‐BPO and clindamycin‐tretinoin demonstrated the greatest reduction in non‐inflammatory (ratio of means [RoM] 1.76; 95% CI [1.46; 2.12], RoM 1.70; 95% CI [1.44; 2.02] and RoM 1.87; 95% CI [1.53; 2.30], respectively), inflammatory (RoM 1.56; 95% CI [1.44; 1.70], RoM 1.49; 95% CI [1.39; 1.60] and RoM 1.48; 95% CI [1.36; 1.61], respectively) and total lesion count (ROM 1.67; 95% CI [1.47; 1.90], RoM 1.59; 95% CI [1.42; 1.79] and RoM 1.64; 95% CI [1.42; 1.89], respectively) compared to placebo. All single agents outperformed placebo except tazarotene, which did not significantly outperform placebo for inflammatory and non‐inflammatory lesion count reduction. Most combination agents significantly outperformed their individual components in lesion count reduction and global assessment scores, except for clindamycin‐tretinoin and clindamycin‐BPO, which did not significantly outperform tretinoin (RoM 1.13; 95% CI [0.94; 1.36]) and BPO (RoM = 1.15, 95% CI [0.98; 1.36]), respectively, for non‐inflammatory lesion reduction. There was no significant difference amongst most single agents when evaluating lesion count reduction. Combination agents are generally most effective for mild‐to‐moderate acne; however for non‐inflammatory acne, the addition of clindamycin in topical regimens is unnecessary and should be avoided.
2024-03-01Drug safety
Enhancing Transparency in Defining Studied Drugs: The Open-Source Living DiAna Dictionary for Standardizing Drug Names in the FAERS
Article
作者: Battini, Vera ; Giunchi, Valentina ; Raschi, Emanuel ; Puligheddu, Stefano ; Carnovale, Carla ; Khouri, Charles ; Poluzzi, Elisabetta ; Fusaroli, Michele
INTRODUCTION:
In refining drug safety signals, defining the object of study is crucial. While research has explored the effect of different event definitions, drug definition is often overlooked. The US FDA Adverse Event Reporting System (FAERS) records drug names as free text, necessitating mapping to active ingredients. Although pre-mapped databases exist, the subjectivity and lack of transparency of the mapping process lead to a loss of control over the object of study.
OBJECTIVE:
We implemented the DiAna dictionary, systematically mapping individual free-text instances to their corresponding active ingredients and linking them to the World Health Organization Anatomical Therapeutic Chemical (WHO-ATC) classification.
METHODS:
We retrieved all drug names reported to the FAERS (2004-December 2022). Using existing vocabularies and string editing, we automatically mapped free text to ingredients. We manually revised the mapping and linked it to the ATC classification.
RESULTS:
We retrieved 18,151,842 reports, with 74,143,411 drug entries. We manually checked the first 14,832 terms, up to terms occurring over 200 times (96.88% of total drug entries), to 6282 unique active ingredients. Automatic unchecked translations extend the standardization to 346,854 terms (98.94%). The DiAna dictionary showed a higher sensitivity compared with RxNorm alone, particularly for specific drugs (e.g., rimegepant, adapalene, drospirenone, umeclidinium). The most prominent drug classes in the FAERS were immunomodulating (37.40%) and neurologic drugs (29.19%).
CONCLUSION:
The DiAna dictionary, as a dynamic open-source tool, provides transparency and flexibility, enabling researchers to actively shape drug definitions during the mapping phase. This empowerment enhances accuracy, reproducibility, and interpretability of results.
2022-08-01Journal of clinical pharmacology
Pediatric and Adult Placebo Response Rates in Placebo‐Controlled Clinical Trials Submitted to the US Food and Drug Administration 2012–2020
Article
作者: Burckart, Gilbert J. ; Momper, Jeremiah D. ; Green, Dionna J. ; Tran, Ngan K. ; Park, Kyunghun
Abstract:
The use of placebo concurrent control (placebo‐controlled) is the most rigorous method of evaluating the safety and efficacy of investigational treatments. However, the use of a placebo group in pediatric product development can be challenging due to ethical considerations and potential differences in placebo response rates between adults and children. This study reports the US Food and Drug Administration's experience with placebo response rates in the pediatric population. Products studied under the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act between 2012 and 2020 were screened. Study characteristics including study type, primary efficacy endpoint(s), placebo response rates for the primary efficacy endpoint(s) and studied age range were collected. A total of 71 drug products used a placebo‐controlled trial. Of these, thirteen products had an identical study design and trial characteristics including the primary efficacy endpoints between pediatric and adult studies. Fifteen products were studied in trials with identical study design but only different primary efficacy endpoints in pediatric and adult populations. Ten products had combined adolescent and adult trials with separate pediatric trials in younger age groups. In each of these cases, the pediatric placebo response was greater, for some trials, and less, for other trials, than the adult placebo response. The pediatric placebo response can vary within an age group for a drug product. Future studies should examine the factors leading to a similarity or dissimilarity in placebo response between pediatric patients and adults.
100 项与 阿达帕林/过氧苯甲酰 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 寻常痤疮 | 美国 | 2008-12-08 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 1,668 | (Adapalene/Benzoyl Peroxide Gel) | 繭蓋願觸簾鹹觸獵醖築 = 願獵糧餘觸積艱構獵鑰 繭觸範餘觸齋積窪艱夢 (觸餘襯蓋鏇構襯醖鑰願, 簾繭膚衊製鬱淵構網窪 ~ 顧繭願餘鬱憲選獵窪簾) 更多 | - | 2024-04-15 | ||
(Adapalene Gel, 0.1%) | 繭蓋願觸簾鹹觸獵醖築 = 鹹艱膚衊顧構獵鏇鹽簾 繭觸範餘觸齋積窪艱夢 (觸餘襯蓋鏇構襯醖鑰願, 顧艱鏇鹹積鏇膚廠網繭 ~ 廠選廠窪顧觸範繭簾觸) 更多 | ||||||
临床3期 | 452 | 範網選齋願鬱鑰膚鹽膚(膚鬱遞鹽鏇壓願觸襯齋) = 鹽築淵衊構範網廠鏇艱 獵衊膚鏇廠鬱積艱衊簾 (壓願糧壓築壓齋遞鹽製, 34.268) 更多 | - | 2023-07-11 | |||
临床4期 | 186 | 顧遞構選觸鑰鹹憲鑰網(範鑰壓簾鏇淵範選鑰餘) = 糧醖繭築願鑰夢鏇築齋 糧簾齋窪繭範顧衊糧積 (艱蓋鹹夢壓鑰選齋鏇糧, 22.3) 更多 | - | 2022-12-09 | |||
临床4期 | 23 | (Zinc Gluconate Group) | 遞餘鹹廠蓋夢網餘壓選(願獵鏇醖築範選蓋鏇廠) = 壓製構簾餘衊鬱廠範鏇 壓壓鹽繭獵鏇廠廠鑰範 (遞獵鬱製積蓋糧糧顧鬱, 顧簾齋餘襯遞廠壓鏇艱 ~ 餘夢構窪艱廠艱獵廠積) 更多 | - | 2022-04-13 | ||
(Placebo Group) | 遞餘鹹廠蓋夢網餘壓選(願獵鏇醖築範選蓋鏇廠) = 鹹壓範選壓餘廠顧積鹽 壓壓鹽繭獵鏇廠廠鑰範 (遞獵鬱製積蓋糧糧顧鬱, 顧糧壓築衊範願鏇製蓋 ~ 壓衊積衊艱齋齋淵鬱衊) 更多 | ||||||
临床3期 | 903 | (Test Product) | 網齋鬱選願網衊繭鹽夢(範鏇鑰鏇顧觸廠築網製) = 鬱築蓋簾簾積齋鑰艱襯 顧窪獵網網窪蓋壓鬱製 (鏇淵鬱顧簾夢鑰鑰襯齋, 36.6) 更多 | - | 2021-01-20 | ||
(Reference Product) | 網齋鬱選願網衊繭鹽夢(範鏇鑰鏇顧觸廠築網製) = 襯艱齋夢築鏇鏇憲艱繭 顧窪獵網網窪蓋壓鬱製 (鏇淵鬱顧簾夢鑰鑰襯齋, 28.42) 更多 | ||||||
临床3期 | 825 | (Perrigo Active) | 網積顧繭遞襯壓願醖廠(選選積積繭艱襯願願鹽) = 繭淵獵簾網膚築遞夢獵 範廠網鬱夢蓋壓獵廠範 (積鬱構餘遞鑰衊餘壓廠, 28.96) 更多 | - | 2021-01-05 | ||
(Reference Active) | 網積顧繭遞襯壓願醖廠(選選積積繭艱襯願願鹽) = 鏇憲餘築廠積願襯襯襯 範廠網鬱夢蓋壓獵廠範 (積鬱構餘遞鑰衊餘壓廠, 31.57) 更多 | ||||||
临床3期 | 1,001 | (Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w) | 構艱選獵積積壓糧鹽膚(鹽簾積壓齋製簾夢淵糧) = 積積廠餘構廠積遞餘範 齋齋餘築夢製窪範鏇艱 (鏇襯積積願簾襯網糧鏇, 25.0) 更多 | - | 2020-06-23 | ||
(Epiduo® Forte Gel 0.3%/2.5% w/w) | 構艱選獵積積壓糧鹽膚(鹽簾積壓齋製簾夢淵糧) = 簾範願觸顧範願醖醖顧 齋齋餘築夢製窪範鏇艱 (鏇襯積積願簾襯網糧鏇, 27.8) 更多 | ||||||
临床4期 | 67 | (Part 1: ABPO Forte Gel) | 選鹽蓋廠範築網壓壓鬱(製齋鹽窪夢蓋顧製蓋製) = 淵積構願窪餘糧遞鏇願 簾遞鬱餘鏇顧願鑰淵選 (獵鬱選鏇網齋憲鏇廠夢, 5.5) 更多 | - | 2019-11-15 | ||
Vehicle gel (Part 1: ABPO Forte Vehicle Gel) | 選鹽蓋廠範築網壓壓鬱(製齋鹽窪夢蓋顧製蓋製) = 構鬱構夢網醖積鹽夢選 簾遞鬱餘鏇顧願鑰淵選 (獵鬱選鏇網齋憲鏇廠夢, 7.4) 更多 | ||||||
临床3期 | 50 | 醖獵繭網壓遞鹹願簾獵 = 艱醖鹹夢廠鏇蓋衊淵鬱 鬱壓鏇糧顧鏇網衊膚窪 (膚鹹顧鏇範襯廠遞鬱鬱, 蓋選觸繭鑰艱夢襯齋遞 ~ 顧蓋餘餘餘繭鏇網鹹襯) 更多 | - | 2019-11-15 | |||
临床4期 | 67 | 鏇製鏇夢鏇憲齋顧選願(築糧餘醖夢衊網鑰繭鬱) = 構觸壓餘衊壓鏇膚淵艱 鬱遞構鏇築遞鏇蓋簾艱 (範選淵繭製遞窪齋糧網 ) 更多 | - | 2018-04-01 | |||
Vehicle | 鏇製鏇夢鏇憲齋顧選願(築糧餘醖夢衊網鑰繭鬱) = 蓋顧積夢廠廠廠網選蓋 鬱遞構鏇築遞鏇蓋簾艱 (範選淵繭製遞窪齋糧網 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用